



**Office of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

**December 12, 2006 6:30 – 9:00 p.m.**

- 1. Executive Session** **6:30 - 7:00**
  - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Nominations and Election of Chair** **7:00 - 7:05**
- 3. Approval of DUR Board Minutes** **7:05 - 7:10**

(Public Comment Prior to Board Action)
- 4. OVHA Pharmacy Administration Updates** **7:10 - 7:15**
- 5. Medical Director Update** **7:15 - 7:25**
  - Clinical Programs Update
  - Prescriber Comments
- 6. Follow-up Items from Previous Meeting** **7:25 – 7:40**
  - Wellbutrin-XL<sup>®</sup> (bupropion-XL)
  - Travatan Z<sup>®</sup> (travoprost)
  - Pevacid<sup>®</sup> Solutabs
  - Avonex<sup>®</sup>
  - Actonel<sup>®</sup>/Actonel<sup>®</sup> w/Calcium
  - Update to Pharmacies – Zocor<sup>®</sup>/Fluticasone Nasal Inhaler/Other PDL Changes
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **7:40 - 7:55**

(Public comment prior to Board action)

  - Anti-obesity
  - Multiple Sclerosis: Injectables
  - Analgesics: Narcotics-Long Acting (Quantity Limits & Duragesic-12 criteria)
- 8. Clinical Update: New Drug Reviews** **7:55 - 8:15**

(Public comment prior to Board action)

  - Ensam<sup>®</sup> (selegiline)
  - Implanon<sup>®</sup> Implant (etonogestrel)
  - Taclonex<sup>®</sup> (calcipotriene/betamethasone)
- 8. Drug Classes – New** **8:15 – 8:45**
  - Erythropoietins
  - Acne: Topical - Anti-infectives
  - Acne: Topical – Rosacea
  - Acne: Topical – Retinoids
  - Acne: Oral
  - Cardiac Glycosides
  - Anti-infectives: Topical
- 9. RetroDUR** **8:45 - 8:45**

- No topics for discussion

**10. Updated New-to-Market Drug Monitoring Log** **8:45 - 8:55**

**11. General Announcements** **8:55 - 9:00**

- Tamiflu<sup>®</sup> - potential risk of neuropsychiatric events

**12. Adjourn** **9:00**